Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lesko

Showing results (31-40 of 231) with videos related to

Pageof 24
Sort By:
Journal of Clinical Pharmacology|May 18, 2004
Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?Shiew-Mei Huang, Lawrence J Lesko
The Pharmacogenomics Journal|January 13, 2006
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshopR A Salerno, L J Lesko
Annals of Allergy|September 1, 1984
Physical-chemical compatibility of cromolyn sodium nebulizer solution--bronchodilator inhalant solution admixturesL J Lesko, A K Miller
Acta Virologica|October 1, 1993
Canine distemper virus replication in cells on microcarriersJ Lesko, P Veber, E Duseková
Journal of Pharmaceutical Sciences|December 1, 1981
Relative bioavailability of aspirin gumD W Woodford, L J Lesko
Nature Biotechnology|July 2, 2003
Microarray data--the US FDA, industry and academiaJoseph L Hackett, Lawrence J Lesko
Journal of Thrombosis and Thrombolysis|October 2, 2007
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesBrian F Gage, Lawrence J Lesko
Therapeutic Drug Monitoring|January 1, 1980
Two reasons for unusual therapeutic drug monitoring results in hospitalized patientsA T Canada, L J Lesko
American Journal of Hospital Pharmacy|March 1, 1982
Extent of analyst bias in drug-assay resultsL J Lesko, T T Turo
Annual Review of Pharmacology and Toxicology|March 27, 2001
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategiesL J Lesko, A J Atkinson
Pageof 24

Showing results (31-40 of 231) with videos related to

Sort By:
Pageof 24
Journal of Clinical Pharmacology|May 18, 2004
Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?Shiew-Mei Huang, Lawrence J Lesko
The Pharmacogenomics Journal|January 13, 2006
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshopR A Salerno, L J Lesko
Annals of Allergy|September 1, 1984
Physical-chemical compatibility of cromolyn sodium nebulizer solution--bronchodilator inhalant solution admixturesL J Lesko, A K Miller
Acta Virologica|October 1, 1993
Canine distemper virus replication in cells on microcarriersJ Lesko, P Veber, E Duseková
Journal of Pharmaceutical Sciences|December 1, 1981
Relative bioavailability of aspirin gumD W Woodford, L J Lesko
Nature Biotechnology|July 2, 2003
Microarray data--the US FDA, industry and academiaJoseph L Hackett, Lawrence J Lesko
Journal of Thrombosis and Thrombolysis|October 2, 2007
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesBrian F Gage, Lawrence J Lesko
Therapeutic Drug Monitoring|January 1, 1980
Two reasons for unusual therapeutic drug monitoring results in hospitalized patientsA T Canada, L J Lesko
American Journal of Hospital Pharmacy|March 1, 1982
Extent of analyst bias in drug-assay resultsL J Lesko, T T Turo
Annual Review of Pharmacology and Toxicology|March 27, 2001
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategiesL J Lesko, A J Atkinson
Pageof 24